Consistent Revenue Growth: Medtronic reported an 8.4% increase in revenue for Q1 FY26, achieving an organic growth rate of 4.8%, aligned with guidance. The company remains optimistic about maintaining mid-single-digit growth throughout the fiscal year, forecasting an overall organic growth of approximately 5% for FY26, with expectations of acceleration in the second half.

Cardiovascular Segment Performance: The Cardiovascular segment experienced significant growth, particularly in Cardiac Ablation Solutions (CAS), which surged nearly 50% year-over-year. The strong demand and utilization of products such as the Pulsed Field Ablation system underpin this growth. The company anticipates continued momentum, projecting an incremental $1 billion in revenue from CAS on top of FY25 figures.

Neuroscience and MedSurg Challenges: While Neuroscience grew 3% driven by high single digits in Neuromodulation and Neurosurgery, challenges in the Specialty Therapies led to below-trend growth. Similarly, the MedSurg segment grew only 2% due to ongoing market pressures in bariatric surgery and shifts to robotic procedures. These areas are expected to improve but represent potential headwinds.